Belite Bio Raises $15 Million Through Registered Direct Offering

Belite Bio has announced a registered direct offering of $15 million to a single large existing institutional shareholder. The offering includes the sale of 230,770 American Depositary Shares and warrants to purchase 230,770 ADSs at a purchase price of $65 per ADS. The gross proceeds from the offering are expected to be approximately $15 million, with the potential for additional proceeds of up to $15 million from the exercise of five-year warrants. The Company intends to use the net proceeds for working capital and general corporate purposes.

Belite Bio, Inc. (Nasdaq: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases, has announced a registered direct offering of $15 million. The offering includes the sale of 230,770 American Depositary Shares (ADSs) and warrants to purchase 230,770 ADSs at a purchase price of $65 per ADS [2].

The gross proceeds from the offering are expected to be approximately $15 million, with the potential for additional proceeds of up to $15 million from the exercise of five-year warrants. The closing of the offering is expected to occur on or about August 8, 2025, subject to the satisfaction of customary closing conditions. The offering was made to a single large existing institutional shareholder [2].

Belite Bio intends to use the net proceeds from the offering for working capital and general corporate purposes. Titan Partners Group, a division of American Capital Partners, is acting as the sole placement agent for the offering. The offering is being made pursuant to a shelf registration statement on Form F-3 (File No. 333-284521) previously filed with the U.S. Securities and Exchange Commission (the “SEC”) and declared effective on January 27, 2025 [2].

References:
[1] https://www.stocktitan.net/news/offerings.html
[2] https://www.stocktitan.net/news/BLTE/belite-bio-announces-registered-direct-offering-of-15-yhvxf8og32ba.html